3.0.0 652 2026-01-08T20:08:29Z 2026-01-08T20:08:29Z Senate S S 2025-02-20 119 https://www.congress.gov/bill/119th-congress/senate-bill/652 sshr00 Health, Education, Labor, and Pensions Committee Senate Standing Referred To 2025-02-20T18:11:41Z 2025-02-20 sshr00 Health, Education, Labor, and Pensions Committee Senate Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130) IntroReferral 2025-02-20 Introduced in Senate IntroReferral 10000 9 Library of Congress D000563 Sen. Durbin, Richard J. [D-IL] Richard Durbin D IL J. N M001198 Sen. Marshall, Roger [R-KS] Roger Marshall R KS 2025-02-20 True Health Administrative law and regulatory procedures 2025-07-10T15:43:54Z Civil actions and liability 2025-07-10T15:43:41Z Congressional oversight 2025-07-10T15:44:18Z Department of Health and Human Services 2025-07-10T15:43:59Z Government information and archives 2025-07-10T15:44:10Z Health technology, devices, supplies 2025-07-10T15:44:04Z Internet, web applications, social media 2025-07-10T15:43:31Z Manufacturing 2025-07-10T15:44:14Z Marketing and advertising 2025-07-10T15:43:36Z Prescription drugs 2025-07-10T15:43:26Z Health 2025-03-13T15:21:07Z

00 2025-02-20 Introduced in Senate 2026-01-08T20:04:08Z <p><strong>Protecting Patients from Deceptive Drug Ads Act</strong></p><p>This bill establishes civil penalties for false or misleading communications about prescription drugs by certain entities on social media. It also requires additional disclosures and reporting relating to drug advertisements on social media or via telehealth.</p><p>The bill’s civil penalties apply when social media influencers or health care providers make communications regarding prescription drugs, using social media platforms, from which they financially benefit that (1) are made knowingly or recklessly and are&nbsp;false or inaccurate, or (2) fail to include the brief summary information (i.e., side effects, contraindications, effectiveness) required in drug advertisements.&nbsp;The Food and Drug Administration (FDA) must issue guidance and publish notice of such enforcement actions. The FDA may notify drug manufacturers when such communications fail to include the brief summary information.</p><p>The bill also requires&nbsp;telehealth providers (i.e., entities that use telecommunications to bring together patients and drug prescribers or dispensers) to include the brief summary information in prescription drug advertisements.</p><p>Also, payments from drug manufacturers to health care providers or social media influencers, or from health care providers to influencers, for communications promoting prescription drugs must be reported in accordance with anti-kickback laws for federal health care programs.</p><p>Additionally,&nbsp;the FDA may conduct market surveillance regarding prescription drug promotion on social media, including analyzing communications and establishing a task force with the Federal Trade Commission.</p>

Display Title 45 2025-03-13T01:23:24Z Short Title(s) as Introduced 101 2025-03-13T01:23:20Z Introduced in Senate IS Official Title as Introduced 6 2025-03-13T01:18:36Z Introduced in Senate IS Introduced in Senate 2025-02-20T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-119s652is/xml/BILLS-119s652is.xml 2025-02-20 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130) text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.